[Tyrosine kinase inhibitor-associated choroidopathy]

Ophthalmologe. 2020 Jun;117(6):566-570. doi: 10.1007/s00347-019-00964-y.
[Article in German]

Abstract

A 66-year-old male patient presented to the ophthalmology department with bilateral blurred vision, which had persisted for 1 week. Due to a pulmonary melanoma metastasis, the patient received a combination treatment with dabrafenib and trametinib. At the first presentation visual acuity was 1.2 on the right and 1.0 on the left. A normotensive intraocular pressure was measured in both eyes. Fundoscopy showed bilateral white, areolar alterations in the choroid and choroid folds and in the left eye a bullous choroidal detachment. Bilateral neurosensory detachment and subretinal fluid were found in optical coherence tomography (OCT). After reduction of the local treatment for pressure reduction and under local and systemic anti-inflammatory treatment, the choroidal swelling was progressive, the visual acuity dropped to 0.5 in the right and to 0.1 in the left eye. A significant regression of the findings occurred only after pausing the treatment with trametinib. Visual acuity rose to 1.0 (left) and 0.8 (right). The OCT showed a dry macula on the right and a small amount of residual subretinal fluid in the left eye.

Keywords: Choroidal detachment; Malignant melanoma of the skin; Ocular hypotony; Tumor associated retinal detachment; Tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Choroid
  • Choroid Diseases* / chemically induced
  • Fluorescein Angiography
  • Humans
  • Male
  • Protein Kinase Inhibitors / adverse effects*
  • Retinal Detachment*
  • Tomography, Optical Coherence

Substances

  • Protein Kinase Inhibitors